SUMMARY
BackgroundAfter radiotherapy for pelvic cancer, gastrointestinal symptoms affecting quality of life are common. How they affect daily living is unknown.
One hundred inpatients in a hospital-based Trauma Program in the USA were interviewed with the Dissociative Trance Disorder Interview Schedule (DTDIS). There were no significant differences for the DTDIS total score or any of the subscale scores on test-retest: all t-values comparing the two administrations of the DTDIS were below 0.7, and all p-values were above 0.5. Cronbach's alpha for the US sample was 0.966 and for the Israeli sample it was 0.971. The findings indicate that the DTDIS has good reliability and may be suitable for use in cross-cultural research; however, the results require replication by independent researchers in a variety of cultures and languages, and in both clinical and nonclinical samples.
Thirty-seven inpatients in a hospital-based Trauma Program completed a set of measures at admission and at 6 and 10-months follow-up. On the Dissociative Disorders Interview Schedule, the average number of secondary features of dissociative identity disorder at baseline was 3.6 (SD ⇤ 4.2), and the average score on the Dissociative Experiences Scale (DES) was 37.8 (SD ⇤ 21.9). At 10 months follow-up, average scores on the DES had declined significantly from 37.8 to 31.1; average scores on the Beck Depression Inventory-II had declined from 36.9 to 24.3; and average scores on the Somatoform Dissociation Questionnaire had declined from 41.5 to 32.5. Treatment outcomes for complex dissociative disorders are supported by replicated prospective studies and are evidence based at Level II according to the criteria of the United States Preventive Services Task Force
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.